Name Dosage Indications

Bendroflumethiazide  Adults and children aged 12 For the treatment of high

years and over: blood pressure and
Oedema: management of edema
Initially 5-10mg once daily or related to heart failure.
on alternate days.
Maintenance: 2.5-10mg two
or three times weekly.

Hypertension: 2.5-5mg once
daily. When
Bendroflumethiazide is used
concurrently with other
specific hypotensive agents,
the dosage of such agents
should be reduced and then
adjusted as necessary.
Paediatric population

Children under 12
years: Initial dose of
400micrograms/kg of body
weight daily reducing to the
maintenance dose of 50-
100micrograms/kg daily.
A more appropriate dosage
form may be required.

Elderly: Dosage may need to

be reduced in the elderly,
especially where there is
impairment of renal function.

Benzthiazide Usual Adult Dose for

Hypertension For the treatment of high
25 to 50 mg orally twice a day blood pressure and
after meals. management of edema.

Usual Adult Dose for Edema

Initial dose: 25 to 100 mg
orally twice a day after meals.
Maintenance dose: 50 to 150
mg/day orally in 2 to 3 divided
doses.
 Renal Dose Adjustments
CrCl < 25 mL/min: Not
recommended.
CrCl 25-80 mL/min: Initial
dose: 25 mg orally twice a day
after meals. Maintenance
dose: 50 to 100 mg/day orally
in a single or 2 divided doses.
Chlorothiazide Edema
0.5-1 g (10 to 20 mL) PO/IV
qDay or q12hr; many patients
with edema respond to
intermittent therapy (ie,
administration on alternate
days or 3-5 days each week;
reduces risk of undesirable
electrolyte imbalance)
Hypertension
0.5 -1 g (10-20 mL)/day PO/IV
as single or divided dose;
increase or decrease dosage
based on blood pressure
response
Hydroflumethiazide Usual Adult Dose for Edema
Initial dose: 50 mg orally twice
a day.
Maintenance dose: 50 to 100
mg/day orally.
Renal Dose Adjustments
CrCl less than 25 mL/min: Not
recommended.
CrCl 25 to 80 mL/min: Initial
dose: 25 mg orally once or
twice a day.
Maintenance dose: 25 to 200
mg/day orally.
Chlorothiazide is indicated as
adjunctive therapy in edema
associated with congestive
heart failure, hepatic cirrhosis,
and corticosteroid and
estrogen therapy. It is also
indicated in the management
of hypertension either as the
sole therapeutic agent or to
enhance the effectiveness of
other antihypertensive drugs
in the more severe forms of
hypertension.
Used as adjunctive therapy in
edema associated with
congestive heart failure,
hepatic cirrhosis, and
corticosteroid and estrogen
therapy. Also used in the
management of hypertension
either as the sole therapeutic
agent or to enhance the effect
of other antihypertensive
drugs in the more severe
forms of hypertension.
Methyclothiazide Hypertension
2.5-5 mg PO qDay; if not
controlled after 8-12 weeks,
consider adding another
antihypertensive agent
Edema
Indicated to relieve edema
associated with congestive
heart failure, hepatic cirrhosis, heart failure, hepatic cirrhosis,
and corticosteroid and
estrogen therapy
2.5 mg PO qDay; if needed,
may increase, not to exceed
10 mg PO qDay
For use in the management of
hypertension either as the
sole therapeutic agent or to
enhance the effect of other
antihypertensive drugs in the
more severe forms of
hypertension. Also used as
adjunctive therapy in edema
associated with congestive
and corticosteroid and
estrogen therapy.

Trichlormethiazide Usual Adult Dose for Edema Used in the treatment of

2-4 mg per day orally in 1-2 oedema (including that
divided doses. associated with heart failure)
Usual Adult Dose for and hypertension.

Hypertension
2-4 mg per day orally in 1-2
divided doses.

Renal Dose Adjustments

CrCl < 25 mL/min: Not
recommended.

CrCl 25-80 mL/min: Initial

dose: 2 mg orally once a day.
Maintenance dose: 2-4
mg/day as a single or 2
divided doses.

THIAZIDE LIKE MEDICATIONS

NAME DOSAGE INDICATION

Indapamide Adults  Edema associated with
 Edema – 2.5 mg/day CHF
PO as single dose in  Hypertension, as sole
the morning. May be therapy or in
 increased to 5 mg/day combination with
is response is not other
satisfactory after 1 wk. antihypertensives
 Hypertension – 1.25  Unlabeled use:
mg/day PO. May be Diabetes insipidus,
increased up to 2.5 especially nephrogenic
mg/day if response is diabetes insipidus
not satisfactory after 4
wks. May increase to a
maximum of 5
mg/day. If
combination
antihypertensive
therapy is needed,
reduce the dosage of
other drugs by 50%,
then adjust according
to patient’s response.
Quinethazone  Edema: Usual dose Indications include edema
range – 25-200 mg/d associated with congestive
as a single dose in the heart failure, hepatic cirrhosis
morning or in 2 with ascites, corticosteroid
divided doses and estrogen therapy, and
Intermittent therapy some forms of renal function
may be safer and more impairment including
effective and is nephrotic syndrome, acute
performed by gibing glomerulonephritis, and
the dose every other chronic renal failure.
day or on a 3-5 d/wk
schedule. Hypertension (treatment)—
 Hypertension: Usual Thiazide diuretics are
dose range – 25-100 indicated either alone or as
mg/d as a single dose adjunctive therapy in the
in the morning or in 2 treatment of hypertension
divided doses
Metolazone Adults  Adjunctive therapy in
Zaroxolyn edema associated with
 Hypertension: 2.5-5 CHF, cirrhosis,
mg daily PO corticosteroid and
 Edema of renal estrogen therapy,
disease: 5-20 mg daily renal dysfunction.
PO  Hypertension, as
 Edema of CHF: 5-20 monotherapy or in
mg daily PO combination with
 other
antihypertensives.
 Unlabeled uses:
Calcium
nephrolithiasis alone
of with amiloride or
allopurinol to prevent
recurrences in
hypercalciuric or
normal calciuric
patients; diabetes
insipidus, especially
nephrogenic diabetes
insipidus.
Chlorthalidone  Edema – 50-100  Adjunctive therapy in
mg/day PO (30-60 mg edema associated with
Thalitone) or 100 mg CHF, cirrhosis,
every other day; up to corticosteroid and
200 mg/day. estrogen therapy,
 Hypertension: Initiate renal dysfunction
with 25 mg/day; if  Hypertension alone of
response is with other
insufficient, increase antihypertensives
to 50 mg/day. Usual
range, 25-100 mg/day
PO based on patient
response.